New head of protein services joins RSSL

Nicholas Michael has 10 years of experience in mass spectrometry and HPLC

RSSL has appointed Nicholas Michael as Senior Scientist to head up the company's protein characterisation services.

With 10 years' experience in mass spectrometry and HPLC, Michael previously worked at Cancer Research and Lonza Biologics. Protein characterisation, including glycosylation profiling and impurity profiling, is one of several GMP services that RSSL offers to the pharmaceutical/biopharma industry.

You may also like

Analysis

RSSL expands investigative capabilities with NMR spectroscopy

RSSL has enhanced its investigative and quality control capabilities with the installation of a new 600 MHz Bruker AVANCE NEO NMR spectrometer
Analysis

Nitrosamines analysis - better understanding the risk

RSSL webinar will take place Wednesday 3 February 2021, 2.00pm – 3.00pm (GMT)
Analysis

RSSL launches nitrosamine test service

In response to the new nitrosamines regulations, RSSL have extended their pharmaceutical risk assessment capabilities, developing a single, overarching analytical method to successfully overcome the complexities of the testing process and provide much-needed support to the sector
Analysis

RSSL launches bespoke nitrosamine test service

Reading Scientific Services Ltd (RSSL) has expanded its pharmaceutical assessment capabilities with the introduction of a robust analytical method designed to determine the presence of nitrosamines
Regulatory

Ethypharm and RSSL partnership fast-tracks priority medicine

Ethypharm has collaborated with RSSL to accelerate the manufacture and batch release of fentanyl injection
Research & Development

RSSL launches same day mycoplasma testing service

If a manufacturer gets a sample to RSSL by 9:30am, it will receive mycoplasma testing results by 5pm
Analysis

Detection and quantitation of residual host cell DNA

This white paper by Phil Kuhlman, Biopharmaceutical Technical Specialist at RSSL, discusses an approach to monitoring the levels of residual DNA derived from the production host for the drug including consideration of practical control of contamination as well as the MHRA’s guidance on performing PCR analysis
Subscribe now